Plus Therapeutics (PSTV) Receivables - Other (2011 - 2026)

Plus Therapeutics (PSTV) has 14 years of Receivables - Other data on file, last reported at $1.3 million in Q1 2026.

• Receivables - Other for Q1 2026 came in at $1.3 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $1.3 million (changed N/A YoY), and the FY2025 annual result was $322000.0, down 43.61% from the prior year.
• Receivables - Other advanced to $1.3 million in Q1 2026 per PSTV's latest filing, from $322000.0 in the prior quarter.
• Over five years, Receivables - Other peaked at $1.3 million in Q1 2026 and troughed at $73000.0 in Q3 2022.
• A 5-year average of $592285.7 and a median of $571000.0 in 2024 frame the typical range for Receivables - Other.
• The sharpest annual moves came in 2023 and 2025: Receivables - Other climbed 24.66% in 2023, then plunged 43.61% in 2025.
• A 5-year view of Receivables - Other shows it stood at $73000.0 in 2022, then advanced by 24.66% to $91000.0 in 2023, then jumped by 527.47% to $571000.0 in 2024, then sank by 43.61% to $322000.0 in 2025, then soared by 319.25% to $1.3 million in 2026.
• Business Quant data shows PSTV's Receivables - Other at $1.3 million in Q1 2026, $322000.0 in Q4 2025, and $1.0 million in Q2 2025.